Thrombophilia cost-effectiveness of therapy

Thrombophilia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Thrombophilia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Thrombophilia cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Thrombophilia cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Thrombophilia cost-effectiveness of therapy
CDC on Thrombophilia cost-effectiveness of therapy
Thrombophilia cost-effectiveness of therapy in the news
Blogs on Thrombophilia cost-effectiveness of therapy
Directions to Hospitals Treating Thrombophilia
Risk calculators and risk factors for Thrombophilia cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Asiri Ediriwickrema, M.D., M.H.S. [2]

Overview

• It is important to determine which patients require screening for thrombophilia, and subsequently which patients require treatment.
• Certain clinical scenarios may warrant thrombophilia screening.
• Unnecessary thrombophilia screening can lead to increased costs.